Literature DB >> 8639015

Cholesterol-lowering intervention program. Effect of the step I diet in community office practices.

A W Caggiula1, J E Watson, L H Kuller, M B Olson, N C Milas, M Berry, J Germanowski.   

Abstract

BACKGROUND: A randomized study was conducted to test the feasibility of cholesterol lowering in physician office practices using the National Cholesterol Education Program Adult Treatment Panel 1 guidelines.
METHODS: Twenty-two physician practices in phase 1 and 23 in phase 2 were recruited from communities in Western Pennsylvania and West Virginia. These physicians treated a total of 450 adults in phase 1 (190 men and 260 women) and 480 adults in phase 2 (184 men and 296 women) with hypercholesterolemia. Three models (Usual Care [phase 1], Office Assisted [phase 2], and Nutrition Center [phase 2]) for implementing the National Cholesterol Education Program Adult Treatment Panel 1 guidelines were tested over an 18-month period. The baseline serum cholesterol levels were as follows: 6.51 mmol/L (252 mg/dL) in the Usual Care Model; 6.80 mmol/L (262 mg/dL) in the Office Assisted Model; and 6.96 mmol/L (269 mg/dL) in the Nutrition Center Model.
RESULTS: In the patients who were not taking lipid-lowering medication, the mean cholesterol response was significantly different between the 3 models (P < .01). Serum cholesterol levels declined by 0.14 mmol/L (5.4 mg/dL) in the Usual Care Model; by 0.31 mmol/L (12 mg/dL) in the Office Assisted Model; and by 0.54 mmol/L (20.9 mg/dL) in the Nutrition Center Model. Two factors-length of time to follow-up measurement and change in weight-were independently related to cholesterol response across all models. African Americans demonstrated a significantly smaller response than whites in the Usual Care Model, while men demonstrated greater declines in serum cholesterol levels than women in the Office Assisted Model. Patient satisfaction was very favorable in both enhanced conditions; however, those treated in the the Nutrition Center Model were more satisfied (P < .05) with program components.
CONCLUSIONS: The impact of nutrition intervention delivered through physician practices on serum cholesterol levels is less than clinically desirable, and new approaches with more aggressive therapy should be tested and implemented.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8639015     DOI: 10.1001/archinte.156.11.1205

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  10 in total

Review 1.  Reduced or modified dietary fat for preventing cardiovascular disease.

Authors:  Lee Hooper; Carolyn D Summerbell; Rachel Thompson; Deirdre Sills; Felicia G Roberts; Helen J Moore; George Davey Smith
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

Review 2.  Pravastatin. A pharmacoeconomic review of its use in primary and secondary prevention of coronary heart disease.

Authors:  A J Coukell; M I Wilde
Journal:  Pharmacoeconomics       Date:  1998-08       Impact factor: 4.981

Review 3.  Simvastatin. A reappraisal of its cost effectiveness in dyslipidaemia and coronary heart disease.

Authors:  K L Goa; L B Barradell; D McTavish
Journal:  Pharmacoeconomics       Date:  1997-01       Impact factor: 4.981

4.  A systematic review of the use of theory in the design of guideline dissemination and implementation strategies and interpretation of the results of rigorous evaluations.

Authors:  Philippa Davies; Anne E Walker; Jeremy M Grimshaw
Journal:  Implement Sci       Date:  2010-02-09       Impact factor: 7.327

5.  Insoluble carob fiber rich in polyphenols lowers total and LDL cholesterol in hypercholesterolemic sujects.

Authors:  Baltasar Ruiz-Roso; José C Quintela; Ester de la Fuente; Javier Haya; Lourdes Pérez-Olleros
Journal:  Plant Foods Hum Nutr       Date:  2010-03       Impact factor: 3.921

Review 6.  Reduced or modified dietary fat for preventing cardiovascular disease.

Authors:  Lee Hooper; Carolyn D Summerbell; Rachel Thompson; Deirdre Sills; Felicia G Roberts; Helen Moore; George Davey Smith
Journal:  Cochrane Database Syst Rev       Date:  2011-07-06

Review 7.  Pharmacoeconomics of lipid-lowering agents for primary and secondary prevention of coronary artery disease.

Authors:  J W Hay; W M Yu; T Ashraf
Journal:  Pharmacoeconomics       Date:  1999-01       Impact factor: 4.558

8.  Reduction in saturated fat intake for cardiovascular disease.

Authors:  Lee Hooper; Nicole Martin; Oluseyi F Jimoh; Christian Kirk; Eve Foster; Asmaa S Abdelhamid
Journal:  Cochrane Database Syst Rev       Date:  2020-08-21

9.  Effects of total fat intake on body fatness in adults.

Authors:  Lee Hooper; Asmaa S Abdelhamid; Oluseyi F Jimoh; Diane Bunn; C Murray Skeaff
Journal:  Cochrane Database Syst Rev       Date:  2020-06-01

10.  Reduction in saturated fat intake for cardiovascular disease.

Authors:  Lee Hooper; Nicole Martin; Oluseyi F Jimoh; Christian Kirk; Eve Foster; Asmaa S Abdelhamid
Journal:  Cochrane Database Syst Rev       Date:  2020-05-19
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.